CORT discovers, develops, and sells medications to treat severe metabolic, oncologic, and psychiatric disorders, focusing on the hormone cortisol (over 1,000 proprietary modulators) along with Cushing’s syndrome. Its second-quarter fiscal 2026 earnings report showed record revenue of $256.1 million (a 32% year-over-year rise), net income of $43 million (a 22.9% gain), $545 million in cash and investments, and raised 2026 revenue guidance of up to $1.2 billion.
It’s no wonder CORT shares are up 218% so far this year – and they could rise more. MoneyFlows data shows how Big Money investors are again betting heavily on the stock.
Big Money Buying Corcept
Institutional volumes reveal plenty. In the last year, CORT has enjoyed strong investor demand, which we believe to be institutional support.
Each green bar signals unusually large volumes in CORT shares. They reflect our proprietary inflow signal, pushing the stock higher:
Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Corcept.
Corcept Fundamental Analysis
Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, CORT has had strong sales growth:
- 1-year sales growth rate (+12.8%)
- 3-year sales growth rate (+24.3%)
Source: FactSet
Also, EPS is estimated to ramp higher this year by +108.2%.
Now it makes sense why the stock has been generating Big Money interest. CORT has a track record of strong financial performance.
Marrying great fundamentals with MoneyFlows software has found some big winning stocks over the long term.
Corcept has been a top-rated stock at MoneyFlows for years. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.
It’s drawn 43 outlier inflow signals since 2017 and is up 1,016% in that time. The blue bars below show when CORT was a top pick on the Outlier 20 report in the last five years…institutions continue to buy up shares:
Tracking unusual volumes reveals the power of money flows.
This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.
Corcept Price Prediction
The CORT action isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.
Disclosure: the author holds no position in CORT at the time of publication.
If you are a Registered Investment Advisor (RIA) or a serious investor, take your investing to the next level. MoneyFlows created 11 Frontiers indexes to help serious investors capture AI-driven themes and learn the leading stocks in each Frontier. Get started here.
